Variation | Total (n = 108) | Cohort, median (IQR) | P value | |
---|---|---|---|---|
miR-1231 < 1.775 | miR-1231 ≥ 1.775 | |||
Age (year) | 64.08 ± 7.6 | 64.69 ± 7.76 | 63.48 ± 7.47 | 0.413 |
BMI (kg/m2) | 23.9 ± 3.53 | 23.82 ± 3.75 | 23.98 ± 3.33 | 0.819 |
Serum CEA level (ng/mL) | 3.9 (1.83, 13.43) | 5.92 (2.41, 38.39) | 3.12 (1.47, 6.91) | 0.021* |
Serum CRP level (μmol/L) | 9.49 (2.38, 13.34) | 11 (4.26, 13.28) | 5.99 (2.14, 13.37) | 0.227 |
Albumin level (g/L) | 40.01 ± 5.21 | 39.46 ± 4.83 | 40.57 ± 5.56 | 0.272 |
Neutrophils count (109/L) | 4.68 (3.53, 6.27) | 4.72 (3.67, 6.08) | 4.68 (3.37, 6.4) | 0.549 |
Lymphocytes count (109/L) | 1.68 (1.23, 2.15) | 1.47 (1.18, 2.02) | 1.75 (1.36, 2.3) | 0.073 |
Hemoglobin level (g/L) | 133 (123, 142.25) | 133.5 (123.25, 144.75) | 131.5 (123, 141.75) | 0.412 |
Platelet count (109/L) | 228.5 (186, 289) | 225.5 (183.25, 291) | 243.5 (200.25, 283.25) | 0.365 |
PNI score | 49.22 (44.03, 53.94) | 47.62 (43.12, 51.64) | 50.05 (44.48, 55.7) | 0.101 |
NLR | 2.9 (2.01, 4.49) | 3.19 (2.37, 4.66) | 2.69 (1.86, 3.87) | 0.098 |
Gender (n %) | 0.534 | |||
Female | 34 (31) | 15 (28) | 19 (35) | |
Male | 74 (69) | 39 (72) | 35 (65) | |
Pathologic type (n %) | 0.547 | |||
Adenocarcinoma | 58 (54) | 29 (54) | 29 (54) | |
Mixed lung cancer | 17 (16) | 7 (13) | 10 (19) | |
Large cell lung cancer | 5 (5) | 4 (7) | 1 (2) | |
Squamous carcinoma | 27 (25) | 14 (26) | 13 (24) | |
Others | 1 (1) | 0 (0) | 1 (2) | |
Metastasis, n (%) | 0.177 | |||
No | 50 (46) | 21 (39) | 29 (54) | |
Yes | 58 (54) | 33 (61) | 25 (46) | |
Stage of NSCLC | 0.005** | |||
Stage I | 17 (16) | 4 (7) | 13 (24) | |
Stage II | 8 (7) | 6 (11) | 2 (4) | |
Stage III | 20 (19) | 6 (11) | 14 (26) | |
Stage IV | 63 (58) | 38 (70) | 25 (46) | |
Surgery (n %) | 0.001** | |||
No | 66 (61) | 42 (78) | 24 (44) | |
Yes | 42 (39) | 12 (22) | 30 (56) | |
Therapy of radiation (n %) | 0.238 | |||
No | 65 (60) | 29 (54) | 36 (67) | |
Yes | 43 (40) | 25 (46) | 18 (33) | |
Application of platinum (n %) | 1 | |||
No | 3 (3) | 2 (4) | 1 (2) | |
Yes | 105 (97) | 52 (96) | 53 (98) | |
Chemotherapy | 0.573 | |||
AP | 45 (42) | 25 (46) | 20 (37) | |
DP | 13 (12) | 6 (11) | 7 (13) | |
EP | 14 (13) | 8 (15) | 6 (11) | |
GP | 8 (7) | 2 (4) | 6 (11) | |
Others | 28 (26) | 13 (24) | 15 (28) | |
Target therapy (n %) | 0.02* | |||
No | 76 (70) | 32 (59) | 44 (81) | |
Yes | 32 (30) | 22 (41) | 10 (19) | |
Application of TKI (n %) | 0.006** | |||
No | 82 (76) | 34 (63) | 48 (89) | |
TKI I | 19 (18) | 15 (28) | 4 (7) | 0.006** |
TKI III | 7 (6) | 5 (9) | 2 (4) | |
Application of VEGF inhibitor, n (%) | 0.775 | |||
No | 94 (87) | 48 (89) | 46 (85) | |
Yes | 14 (13) | 6 (11) | 8 (15) | |
KPS score, n (%) | 0.013* | |||
20 | 1 (1) | 0 (0) | 1 (2) | |
50 | 3 (3) | 2 (4) | 1 (2) | |
60 | 1 (1) | 1 (2) | 0 (0) | |
70 | 9 (8) | 6 (11) | 3 (6) | |
80 | 31 (29) | 22 (41) | 9 (17) | |
90 | 40 (37) | 16 (30) | 24 (44) | |
100 | 23 (21) | 7 (13) | 16 (30) | |
Smoking, n (%) | 1 | |||
No | 51 (47) | 26 (48) | 25 (46) | |
Yes | 57 (53) | 28 (52) | 29 (54) | |
Hypertension, n (%) | 1 | |||
No | 39 (36) | 20 (37) | 19 (35) | |
Yes | 69 (64) | 34 (63) | 35 (65) | |
Hyperlipemia, n (%) | 0.215 | |||
No | 88 (81) | 41 (76) | 47 (87) | |
Yes | 20 (19) | 13 (24) | 7 (13) | |
Heart failure, n (%) | 0.495 | |||
No | 106 (98) | 52 (96) | 54 (100) | |
Yes | 2 (2) | 2 (4) | 0 (0) | |
ACS, n (%) | 1 | |||
No | 105 (97) | 52 (96) | 53 (98) | |
Yes | 3 (3) | 2 (4) | 1 (2) |